Therapy News and Research

RSS

eToims launches new program with leading football franchise to improve athletic therapy

eToims Medical Technology has announced an innovative Sports Development Program with a leading UK football franchise to refine and improve athletic therapy and conditioning.

15 Mar 2011

Cerenis commences CER-001 Phase 2 CHI-SQUARE study in patients with ACS

Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein therapies to treat cardiovascular and metabolic diseases, today announced the start of the Phase 2 CHI-SQUARE study of CER-001 in patients with acute coronary syndrome.

15 Mar 2011

Argentum responds to recent decision in patent lawsuit against Noble Biomaterials

Argentum Medical, LLC today issued a response to the recent decision in their patent infringement litigation versus Noble Biomaterials, Inc.

15 Mar 2011

Bariatric surgery can lead to long-term weight loss, reduce cardiac risk factors in obese adults

Bariatric surgery can result in long-term weight loss and significant reductions in cardiac and other risk factors for some severely obese adults, according to a scientific statement from the American Heart Association.

15 Mar 2011

Research highlights benefit of shortened radiation course for patients with DCIS

Findings by a researcher at The Cancer Institute of New Jersey highlighting the benefit of a shortened radiation course for patients with the most common type of non-invasive breast cancer are part of a feature article in the journal Cancer due out tomorrow.

15 Mar 2011

Cancer Research UK introduces new centre in Oxford

A new centre launched today will cement Oxford's place at the forefront of cancer research, and form one of the final links in a unique chain of Cancer Research UK Centres across the country.

15 Mar 2011

Scientists identify strategy for targeted molecular therapy in liver cancer

In a research study appearing in the journal Cancer Cell on March 14, scientists from Cold Spring Harbor Laboratory and four other institutions have identified a strategy for targeted molecular therapy in liver cancer, which currently has limited treatment options and one of the worst one-year survival rates of any cancer type.

15 Mar 2011

EC grants marketing authorization for Taiho's Teysuno to treat gastric cancer

Taiho Pharmaceutical Co., Ltd., and its parent company, Otsuka Holdings Co., Ltd., announced today that the European Commission has granted marketing authorization for Teysuno, a novel oral anti-cancer agent indicated for the treatment of adults with advanced gastric cancer when given in combination with cisplatin.

15 Mar 2011

Pico-Tesla receives ISO certification for Resonator device

Pico-Tesla, The Magneceutical Company, has received the International Organization for Standardization 13485:2003 certificate for the "design, development, production, manufacture and distribution of resonator systems that generate a low-level electromagnetic field for the therapeutic treatment of disease."

15 Mar 2011

Positive top-line results from IPX066 Phase III study in patients with PD

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced statistically significant, positive, top-line results of the ADVANCE-Parkinson's Disease Phase III clinical study of the safety and efficacy of IPX066 versus immediate-release carbidopa-levodopa in advanced PD patients experiencing motor fluctuations.

15 Mar 2011

Gamida to distribute Health Robotics' CytoCare, i.v.STATION, i.v.SOFT technologies in Israel

Health Robotics today announced that it recently signed an exclusive distribution agreement for its CytoCare, i.v.STATION, and i.v.SOFT world-leading technologies with Israel-based medical technology leader Gamida MedEquip Ltd.

14 Mar 2011

Omthera to fund Epanova Phase 3 development with $33.9 million in Series B funding

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.

14 Mar 2011

HemaCare reports $7.0 million revenue for fourth quarter 2010

HemaCare Corporation announced today that the Company generated fourth quarter revenue of $7.0 million and a net loss of $197,000, or $0.02/share, compared to fourth quarter 2009 revenue of $8.2 million and net income of $195,000, or $0.02/share.

14 Mar 2011

Researchers discover new gene for Sensenbrenner syndrome

Dutch researchers of the Radboud University Medical Center in Nijmegen found a new gene for Sensenbrenner syndrome (Journal of Medical Genetics, 2011 Mar 4). The mutation adds support to the hypothesis that defects in ciliar transport are the cause of the disease. Project leader Dr. Heleen H. Arts is supported by a Kolff Junior Postdoc Grant of the Dutch Kidney Foundation.

14 Mar 2011

Transcept initiates enrollment in TO-2061 Phase 2 study for treatment resistant obsessive compulsive disorder

Transcept Pharmaceuticals, Inc. today announced the first patient has been enrolled in a Phase 2 clinical study to evaluate TO-2061 as an adjunctive treatment for obsessive compulsive disorder (OCD) in patients who have responded inadequately to currently approved treatments. OCD affects 1 to 2 percent of the United States adult population and can significantly impair the lives of patients and their families.

14 Mar 2011

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that the first patient has been dosed in its pivotal Phase III EVOLVE (EpanoVa fOr Lowering Very high triglyceridEs) trial for Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega-3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

14 Mar 2011

Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis

Anacor Pharmaceuticals announced today that it has completed enrollment in its Phase 2b trial of AN2728, a topical anti-inflammatory product candidate for the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the United States and over 100 million people worldwide.

14 Mar 2011

EvaluatePharma data shows poor R&D productivity measures both in quality, quantity

Pharmaceutical R&D productivity is consistently undercounted. Most reports fail to fully count the number of new drugs that reach the market, missing out on billions of dollars of sales generated by R&D investment, an analysis of EvaluatePharma data shows.

14 Mar 2011

ChronTech initiates ChronVac-C DNA vaccine Phase IIb study against HCV

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its partner, ChronTech Pharma AB, has initiated a Phase IIb clinical study of its ChronVac-C DNA vaccine for hepatitis C virus, delivered by Inovio's proprietary electroporation DNA vaccine delivery technology, in combination with standard of care.

14 Mar 2011

Life Technologies receives FDA 510(k) clearance for StemPro MSC SFM device

Life Technologies Corporation today announced it has received FDA 510(k) clearance for StemPro MSC SFM – a first for this next-generation stem cell culture medium that is now cleared as a medical device and satisfies a crucial requirement for researchers involved in clinical trials in the United States.

14 Mar 2011

Therapy News and Research

eToims launches new program with leading football franchise to improve athletic therapy

Cerenis commences CER-001 Phase 2 CHI-SQUARE study in patients with ACS

Argentum responds to recent decision in patent lawsuit against Noble Biomaterials

Bariatric surgery can lead to long-term weight loss, reduce cardiac risk factors in obese adults

Research highlights benefit of shortened radiation course for patients with DCIS

Cancer Research UK introduces new centre in Oxford

Scientists identify strategy for targeted molecular therapy in liver cancer

EC grants marketing authorization for Taiho's Teysuno to treat gastric cancer

Pico-Tesla receives ISO certification for Resonator device

Positive top-line results from IPX066 Phase III study in patients with PD

Gamida to distribute Health Robotics' CytoCare, i.v.STATION, i.v.SOFT technologies in Israel

Omthera to fund Epanova Phase 3 development with $33.9 million in Series B funding

HemaCare reports $7.0 million revenue for fourth quarter 2010

Researchers discover new gene for Sensenbrenner syndrome

Transcept initiates enrollment in TO-2061 Phase 2 study for treatment resistant obsessive compulsive disorder

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis

EvaluatePharma data shows poor R&D productivity measures both in quality, quantity

ChronTech initiates ChronVac-C DNA vaccine Phase IIb study against HCV

Life Technologies receives FDA 510(k) clearance for StemPro MSC SFM device

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News